Health Care • Biotechnology: Pharmaceutical Preparations
$5.10 ▼ -0.18
(-3.41%)
MKT CAP: $90.6M • VOL: 567.2K
52W L $5 52W H $21
TNXP // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $13.1M | $10.1M | $7.8M |
| YoY Revenue Growth % | +29.8% | +29.9% | — |
| Gross Profit | $6.5M | $2.3M | — |
| Gross Margin % | 49.3% | 23.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$125.7M | -$136.7M | -$118.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$124.0M | -$130.0M | -$116.7M |
| EBITDA (Normalized) | -$123.0M | -$136.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$99.8M | -$60.9M | -$102.0M |
| Capital Expenditures (CapEx) | $3.4M | $120.0K | — |
| Free Cash Flow (FCF) | -$103.2M | -$61.0M | -$102.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $207.6M | $98.8M | — |
| Total Debt (Short + Long Term) | — | $4.7M | — |
| Total Stockholders' Equity | $245.2M | $139.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TNXP.